The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer

Journal of Clinical Oncology

Volumn 23, Issue 16, 2005, Pages 3718-3725

  Nuver, Janine ^a   Smit, Andries J ^a   Wolffenbuttel, Bruce H R ^a   Sluiter, Wim J ^a   Hoekstra, Harald J ^a   Sleijfer, Dirk T ^a   Gietema, Jourik A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ESTRADIOL; ETOPOSIDE; FOLLITROPIN; HYDROCORTISONE; INHIBIN B; LUTEINIZING HORMONE; PRASTERONE SULFATE; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN C; TESTOSTERONE; THYROTROPIN;

ARTICLE; BLOOD SAMPLING; BODY MASS; CANCER CHEMOTHERAPY; CANCER STAGING; CARDIOVASCULAR RISK; CONTROLLED STUDY; FOLLOW UP; HORMONE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPOGONADISM; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; ORCHIECTOMY; PRIORITY JOURNAL; SURVIVAL TIME; TESTIS CANCER; ADULT; AGED; BLOOD; METABOLISM; MIDDLE AGED; SURVIVOR; TESTIS TUMOR; TIME;

ADULT; AGED; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; SEX HORMONE-BINDING GLOBULIN; SURVIVORS; TESTICULAR NEOPLASMS; TESTOSTERONE; TIME FACTORS;

EID: 20544434406     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.02.176     Document Type: Article

References (49)

1. Raghavan D, Cox K, Childs A, et al: Hypercholesterolemia after chemotherapy for testis cancer. J Clin Oncol 10:1386-1389, 1992
2. Boyer M, Raghavan D, Harris PJ, et al: Lack of late toxicity in patients treated with cisplatin-containing combination chemotherapy for metastatic testicular cancer. J Clin Oncol 8:21-26, 1990
3. Bokemeyer C, Berger CC, Kuczyk MA, et al: Evaluation of long-term toxicity after chemotherapy for testicular cancer. J Clin Oncol 14: 2923-2932, 1996
4. Nord C, Fossa SD, Egeland T: Excessive annual BMI increase after chemotherapy among young survivors of testicular cancer. Br J Cancer 88:36-41, 2003
5. Bosl GJ, Leitner SP, Atlas SA, et al: Increased plasma renin and aldosterone in patients treated with cisplatin-based chemotherapy for metastatic germ cell tumors. J Clin Oncol 4:1684-1689, 1986
6. Ellis PA, Fitzharris BM, George PM, et al: Fasting plasma lipid measurements following cisplatin chemotherapy in patients with germ cell tumors. J Clin Oncol 10:1609-1614, 1992
7. Gietema JA, Meinardi MT, van der Graaf WT, et al: Syndrome X in testicular-cancer survivors. Lancet 357:228-229, 2001
8. Nuver J, Smit AJ, Sleijfer DT, et al: Microalbuminuria, decreased fibrinolysis, and inflammation as early signs of atherosclerosis in long-term survivors of disseminated testicuiar cancer. Eur J Cancer 40:701-706, 2004
9. Meinardi MT, Gietema JA, van der Graaf WT, et al: Cardiovascular morbidity in long-term survivors of metastatic testicuiar cancer. J Clin Oncol 18:1725-1732, 2000
10. Huddart RA, Norman A, Shahidi M, et al: Cardiovascular disease as a long-term complication of treatment for testicuiar cancer. J Clin Oncol 21:1513-1523, 2003
11. Fossa SD, Aass N, Harvei S, et al: Increased mortality rates in young and middle-aged patients with malignant germ cell tumors. Br J Cancer 90:607-612, 2004
12. Nord C, Bjoro T, Ellingsen D, et al: Gonadal hormones in long-term survivors 10 years after treatment for unilateral testicuiar cancer. Eur Urol 44:322-328, 2003
13. Phillips GB, Jing T, Heymsfield SB: Relationships in men of sex hormones, insulin, adiposity, and risk factors for myocardial infarction. Metabolism 52:784-790, 2003
14. van den Beld AW, Bots ML, Janssen JA, et al: Endogenous hormones and carotid atherosclerosis in elderly men. Am J Epidemiol 157:25-31, 2003
15. Yang XC, Jing TY, Resnick LM, et al: Relation of hemostatic risk factors to other risk factors for coronary heart disease and to sex hormones in men. Arterioscler Thromb 13:467-471, 1993
16. Haffner SM, Valdez RA, Mykkanen L, et al: Decreased testosterone and dehydroepiandrosterone sulfate concentrations are associated with increased insulin and glucose concentrations in nondiabetic men. Metabolism 43:599-603, 1994
17. Simon D, Preziosi P, Barrett-Connor E, et al: Interrelation between plasma testosterone and plasma insulin in healthy adult men: The Telecom Study. Diabetologia 35:173-177, 1992
18. Laaksonen DE, Niskanen L, Punnonen K, et al: Sex hormones, inflammation and the metabolic syndrome: A population-based study. Eur J Endocrinol 149:601-608, 2003
19. Nestler JE, Clore JN, Blackard WG: Dehydroepiandrosterone: The "missing link" between hyperinsulinemia and atherosclerosis? FASEB J 6:3073-3075, 1992
20. Fraser R, Ingram MC, Anderson NH, et al: Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 33:1364-1368, 1999
21. Carroll PV, Christ ER, Bengtsson BA, et al: Growth hormone deficiency in adulthood and the effects of growth hormone replacement: A review-Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab 83: 382-395, 1998
22. Wake DJ, Walker BR: 11 beta-hydroxysteroid dehydrogenase type 1 in obesity and the metabolic syndrome. Mol Cell Endocrinol 215:45-54, 2004
23. Brennemann W, Stoffel-Wagner B, Helmers A, et al: Gonadal function of patients treated with cisplatin based chemotherapy for germ cell cancer. J Urol 158:844-850, 1997
24. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001
25. Groome NP, Illingworth PJ, O'Brien M, et al: Measurement of dimeric inhibin B throughout the human menstrual cycle. J Clin Endocrinol Metab 81:1401-1405, 1996
26. Vermeulen A, Verdonck L, Kaufman JM: A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84:3666-3672, 1999
27. Zumoff B, Fukushima DK, Hellman L: Intercomparison of four methods for measuring cortisol production. J Clin Endocrinol Metab 38: 169-175, 1974
28. Lin WW, Kim ED, Quesada ET, et al: Unilateral testicular injury from external trauma: evaluation of semen quality and endocrine parameters. J Urol 159:841-843, 1998
29. Willemse PH, Sleijfer DT, Sluiter WJ, et al: Altered Leydig cell function in patients with testicular cancer: Evidence for bilateral testicular defect. Acta Endocrinol (Copenh) 102:616-624, 1983
30. Lahteenmaki PM, Toppari J, Ruokonen A, et al: Low serum inhibin B concentrations in male survivors of childhood malignancy. Eur J Cancer 35:612-619, 1999
31. Wallace EM, Groome NP, Riley SC, et al: Effects of chemotherapy-induced testicular damage on inhibin, gonadotropin, and testosterone secretion: A prospective longitudinal study. J Clin Endocrinol Metab 82:3111-3115, 1997
32. Petersen PM, Skakkebaek NE, Vistisen K, et al: Semen quality and reproductive hormones before orchiectomy in men with testicular cancer. J Clin Oncol 17:941-947, 1999
33. Petersen PM, Skakkebaek NE, Rorth M, et al: Semen quality and reproductive hormones before and after orchiectomy in men with testicular cancer. J Urol 161:822-826, 1999
34. Monsees TK, Franz M, Gebhardt S, et al: Sertoli cells as a target for reproductive hazards. Andrologia 32:239-246, 2000
35. Stuart NSA, Woodroffe CM, Grundy R, et al: Long-term toxicity of chemotherapy for testicular cancer: The cost of cure. Br J Cancer 61:479-184, 1990
36. Leitner SP, Bosl GJ, Bajorunas D: Gonadal dysfunction in patients treated for metastatic germ cell tumors. J Clin Oncol 4:1500-1505, 1986
37. Smith JC, Bennett S, Evans LM, et al: The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 86:4261-4267, 2001
38. Dockery F, Bulpitt CJ, Agarwal S, et al: Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) 104:195-201, 2003
39. Reaven GM: Banting lecture 1988: Role of insulin resistance in human disease. Diabetes 37:1595-1607, 1988
40. Lakka HM, Laaksonen DE, Lakka TA, et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288:2709-2716, 2002
41. Park YW, Zhu S, Palaniappan L, et al: The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988 to 1994. Arch Intern Med 163:427-436, 2003
42. Meigs JB, Wilson PW, Nathan DM, et al: Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52:2160-2167, 2003
43. Shen BJ, Todaro JF, Niaura R, et al: Are metabolic risk factors one unified syndrome? Modeling the structure of the metabolic syndrome X. Am J Epidemiol 157:701-711, 2003
44. Cigolini M, Seidell JC, Targher G, et al: Fasting serum insulin in relation to components of the metabolic syndrome in European healthy men: The European Fat Distribution Study. Metabolism 44:35-40, 1995
45. Thorsen L, Nystad W, Dahl O, et al: The level of physical activity in long-term survivors of testicular cancer. Eur J Cancer 39:1216-1221, 2003
46. Hajamor S, Despres JP, Couillard C, et al: Relationship between sex hormone-binding globulin levels and features of the metabolic syndrome. Metabolism 52:724-730, 2003
47. Skakkebaek NE, Rajpert-De Meyts E, Main KM: Testicular dysgenesis syndrome: An increasingly common developmental disorder with environmental aspects. Hum Reprod 16:972-978, 2001
48. Rhoden EL, Morgentaler A: Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 350: 482-492, 2004
49. Howell SJ, Radford JA, Adams JE, et al: Randomized placebo-controlled trial of testosterone replacement in men with mild Leydig cell insufficiency following cytotoxic chemotherapy. Clin Endocrinol (Oxf) 55:315-324, 2001